z-logo
open-access-imgOpen Access
Bone marrow niches in myelodysplastic syndromes
Author(s) -
Giovanna Tosato,
Jianxun Feng,
Hidetaka Ohnuki,
Minji Sim
Publication year - 2021
Publication title -
journal of cancer metastasis and treatment
Language(s) - English
Resource type - Journals
ISSN - 2394-4722
DOI - 10.20517/2394-4722.2021.120
Subject(s) - cytopenia , bone marrow , haematopoiesis , myelodysplastic syndromes , biology , myeloid , stem cell , hematopoietic stem cell , progenitor cell , myeloid leukemia , immunology , leukemia , epigenetics , cancer research , genetics , gene
Genetic and epigenetic lesions within hematopoietic cell populations drive diverse hematological malignancies. Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms affecting the hematopoietic stem cells characterized by recurrent genetic abnormalities, myelodysplasia (a pathological definition of abnormal bone marrow structure), ineffective hematopoiesis resulting in blood cytopenia, and a propensity to evolve into acute myelogenous leukemia. Although there is evidence that the accumulation of a set of genetic mutations is an essential event in MDS, there is an increased appreciation of the contribution of specific microenvironments, niches, in the pathogenesis of MDS and response to treatment. In physiologic hematopoiesis, niches are critical functional units that maintain hematopoietic stem and progenitor cells and regulate their maturation into mature blood cells. In MDS and other hematological malignancies, altered bone marrow niches can promote the survival and expansion of mutant hematopoietic clones and provide a shield from therapy. In this review, we focus on our understanding of the composition and function of hematopoietic niches and their role in the evolution of myeloid malignancies, with an emphasis on MDS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here